TherapeuticsMD, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	March 31, 2026	December 31, 2025
(Unaudited)
Assets:
Current assets:
Cash and cash equivalents	$8,419	$7,483
Royalty receivable, current portion	3,211	3,525
Prepaid and other current assets	3,633	3,437
Total current assets	15,263	14,445
License rights and other intangible assets, net	3,667	3,761
Right of use assets, net	5,062	5,293
Royalty receivable, long term	13,170	13,713
Other non-current assets	419	444
Total assets	$37,581	$37,656
Liabilities and stockholders’ equity:
Current liabilities:
Accounts payable	$15	$377
Accrued expenses and other current liabilities	2,229	1,741
Current liabilities of discontinued operations	2,667	2,667
Total current liabilities	4,911	4,785
Operating lease liabilities	4,824	5,122
Other non-current liabilities	873	873
Total liabilities	10,608	10,780
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, par value $0.001; 640,000 and 32,000 shares authorized, 11,574 and 11,574 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	11	11
Additional paid-in capital	979,258	979,256
Accumulated deficit	(952,296)	(952,391)
Total stockholders’ equity	26,973	26,876
Total liabilities and stockholders’ equity	$37,581	$37,656

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.